Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer

Purpose: TP53 mutations in early-stage non–small cell lung cancer (NSCLC) may be associated with worse survival but their prognostic role in advanced NSCLC is controversial. In addition, it remains unclear whether mutated patients represent a clinically homogeneous group. Experimental Design: We retrospectively examined TP53 mutations and outcome in a training cohort of 318 patients with stage IIIB–IV NSCLC: 125 epidermal growth factor receptor (EGFR) wild-type (wt) and 193 EGFR mutated (mut). An independent validation cohort of 64 EGFR-mut patients was subsequently analyzed. Mutations were classified as “disruptive” and “nondisruptive” according to their predicted degree of disturbance of the p53 protein structure and function. Results: In the training cohort, TP53 mutations were found in 43 of the 125 EGFR-wt patients (34.4%). Of these, 28 had nondisruptive TP53 mutations and a median overall survival (OS) of 8.5 months, compared with 15.6 months for the remaining 97 patients (P = 0.003). In the EGFR-mut group, TP53 mutations were found in 50 of the 193 patients (25.9%). The OS for the 26 patients with TP53 nondisruptive mutations was 17.8 months versus 28.4 months for the remaining 167 patients (P = 0.04). In the validation cohort, the 11 patients with nondisruptive TP53 mutations had a median OS of 18.1 months compared with 37.8 months for the 53 remaining patients (P = 0.006). In multivariate analyses, nondisruptive TP53 mutations had an independent, significant association with a shorter OS. Conclusions: Nondisruptive mutations in the TP53 gene are an independent prognostic factor of shorter survival in advanced NSCLC. Clin Cancer Res; 20(17); 4647–59. ©2014 AACR.

[1]  S Senan,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  J. Ahn,et al.  Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer , 2013, PloS one.

[3]  F. Végran,et al.  Only Missense Mutations Affecting the DNA Binding Domain of P53 Influence Outcomes in Patients with Breast Carcinoma , 2013, PloS one.

[4]  M. Ladanyi,et al.  Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas , 2013, Cancer.

[5]  Thierry Soussi,et al.  The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis , 2012, Nucleic Acids Res..

[6]  O. Topolcan,et al.  Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer. , 2012, Anticancer research.

[7]  J. Pietenpol,et al.  Targeting mutant p53 in human tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Grossman,et al.  Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl. , 2012, Genes & cancer.

[9]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[10]  U. Moll,et al.  Links between mutant p53 and genomic instability , 2012, Journal of cellular biochemistry.

[11]  M. Olivier,et al.  Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort , 2012, European Respiratory Journal.

[12]  K. Ang,et al.  TP53 Disruptive Mutations Lead to Head and Neck Cancer Treatment Failure through Inhibition of Radiation-Induced Senescence , 2011, Clinical Cancer Research.

[13]  J. Roth,et al.  Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis. , 2011, Clinical lung cancer.

[14]  Š. Pospíšilová,et al.  Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Lambrechts,et al.  Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. , 2011, Nature chemical biology.

[16]  J. Mate,et al.  Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations , 2011, Clinical Cancer Research.

[17]  C. Coffill,et al.  The role of mutant p53 in human cancer , 2011, The Journal of pathology.

[18]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[19]  Jean Louis Fournier,et al.  MUT‐TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancer a , 2010, Human mutation.

[20]  V. Rotter,et al.  Mutant p53 gain-of-function in cancer. , 2010, Cold Spring Harbor perspectives in biology.

[21]  Varda Rotter,et al.  When mutants gain new powers: news from the mutant p53 field , 2009, Nature Reviews Cancer.

[22]  Ya‐Wen Cheng,et al.  Potential Increase in the Prognostic Value of p53 Mutation by Pro72 Allele in Stage I Non-Small-Cell Lung Cancer , 2009, Annals of Surgical Oncology.

[23]  Takayuki Kosaka,et al.  Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  H. Koong,et al.  Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-small Cell Lung Cancer (NSCLC) , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  J. Subramanian,et al.  Molecular genetics of lung cancer in people who have never smoked. , 2008, The Lancet. Oncology.

[26]  Eduardo Sontag,et al.  Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.

[27]  J. Manola,et al.  TP53 mutations and survival in squamous-cell carcinoma of the head and neck. , 2007, The New England journal of medicine.

[28]  L. Seymour,et al.  Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Ming K. Lee,et al.  Cancer-derived p53 mutants suppress p53-target gene expression—potential mechanism for gain of function of mutant p53 , 2007, Nucleic acids research.

[30]  Anindita Das,et al.  Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes , 2004, Oncogene.

[31]  R. Poon,et al.  How Many Mutant p53 Molecules Are Needed To Inactivate a Tetramer? , 2004, Molecular and Cellular Biology.

[32]  Nicole Benoit,et al.  p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. , 2003, Journal of the National Cancer Institute.

[33]  R. Bristow,et al.  Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53 , 2003, Oncogene.

[34]  Yang Xu,et al.  Regulation of p53 responses by post-translational modifications , 2003, Cell Death and Differentiation.

[35]  A. Levine,et al.  The p53 functional circuit. , 2001, Journal of cell science.

[36]  K. Sugimachi,et al.  Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  P. Hainaut,et al.  Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. , 2001, Carcinogenesis.

[38]  Ya‐Wen Cheng,et al.  MDM2 mRNA expression is a favorable prognostic factor in non‐small‐cell lung cancer , 2000, International journal of cancer.

[39]  D. Ryberg,et al.  p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  Y. Yokosaki,et al.  p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: an analysis of medically managed patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  J. Hayashi,et al.  p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. , 1999, Cancer research.

[42]  S. Hirohashi,et al.  Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma , 1999, Oncogene.

[43]  M. Higashiyama,et al.  Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer , 1998, Oncogene.

[44]  J. Jassem,et al.  TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis , 1997, Oncogene.

[45]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[46]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[47]  C. R. Leemans,et al.  Prognostic Significance of Truncating TP53 Mutations in Head and Neck Squamous Cell Carcinoma , 2011, Clinical Cancer Research.

[48]  Lin Huan,et al.  Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .

[49]  Å. Borg,et al.  [Analysis of prognostic value of TP53 gene mutations in non-small cell lung cancer]. , 2005, Pneumonologia i alergologia polska.

[50]  L. Liotta,et al.  Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  E. Jassem,et al.  Analiza rokowniczego znaczenia mutacji genu TP53 u chorych na niedrobnokomorkowego raka pluca , 2005 .